Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. by Ahn, S et al.
Desensitization, internalization, and signaling
functions of -arrestins demonstrated by
RNA interference
Seungkirl Ahn*†, Christopher D. Nelson†‡, Tiffany Runyan Garrison*, William E. Miller§¶, and Robert J. Lefkowitz*‡§
*The Howard Hughes Medical Institute, Departments of ‡Biochemistry and §Medicine, Duke University Medical Center, Durham, NC 27710
Contributed by Robert J. Lefkowitz, December 23, 2002
-Arrestins bind to activated G protein-coupled receptor kinase-
phosphorylated receptors, which leads to their desensitization
with respect to G proteins, internalization via clathrin-coated pits,
and signaling via a growing list of ‘‘scaffolded’’ pathways. To
facilitate the discovery of novel adaptor and signaling roles of
-arrestins, we have developed and validated a generally appli-
cable interfering RNA approach for selectively suppressing
-arrestins 1 or 2 expression by up to 95%. -Arrestin depletion in
HEK293 cells leads to enhanced cAMP generation in response
to 2-adrenergic receptor stimulation, markedly reduced 2-
adrenergic receptor and angiotensin II receptor internalization and
impaired activation of the MAP kinases ERK 1 and 2 by angiotensin
II. This approach should allow discovery of novel signaling and
regulatory roles for the -arrestins in many seven-membrane-
spanning receptor systems.
Despite the diversity of physiological roles played by the largeand ubiquitous family of seven membrane-spanning (7MS)
receptors, there is remarkable conservation of the molecular
mechanisms that mediate and modulate their signaling. Three
families of proteins seem to interact almost universally and in a
stimulus-dependent way with the receptors. These are the het-
erotrimeric G proteins (hence the name G protein-coupled
receptors), the G protein-coupled receptor kinases (GRKs), and
the arrestins. Interaction of an activated 7MS receptor with G
protein leads to dissociation of its  and  subunits, which
activate a variety of effectors (1). Interaction of the activated
receptors with GRKs leads to their phosphorylation on serine
and threonine residues, which is followed by -arrestin binding
(2). Although the mediation of 7MS receptor signaling by G
proteins is reasonably well understood, a full appreciation of the
roles and mechanisms of receptor regulation by arrestins and
GRKs is not yet at hand. Originally discovered as proteins that
mediate the desensitization of receptors (2, 3), the last several
years have seen rapid progress in uncovering an ever-increasing
list of additional functions of this regulatory system. These
include adaptor and scaffold functions that link the receptors to
the clathrin-coated pit endocytosis machinery (4–6) as well as to
a variety of signaling systems such as the mitogen-activated
protein kinases (MAPKs) ERK 1 and 2 (7–10), JNK 3 (11), and
p38 (12).
In contrast with the extraordinarily large superfamily of 7MS
receptors, numbering about a thousand members in the human
genome, both the G protein-coupled receptor kinase and
arrestin families are quite small, with only seven and four genes
known, respectively, in mammals. Of the four arrestin genes, two
are expressed only in retina, whereas two others, termed
-arrestins 1 and 2 (also known as arrestin 2 and 3) are
ubiquitously expressed (13–15). Over the past several years, the
development of knockout (KO) mice in which the genes for
-arrestins 1 and 2 have been inactivated by homologous re-
combination, and of mouse embryonic fibroblasts (MEFs) de-
rived therefrom, have greatly aided the study of the physiological
and cellular roles of these multifunctional proteins (16). How-
ever, the likely possibility that the arrestins might play previously
unsuspected roles in other signaling pathways in diverse cell
types has indicated the need for a generally applicable and
reliable method for selectively suppressing -arrestin isoform
expression in cultured cells. Highly specific posttranscriptional
gene silencing using 21- to 23-nt small interfering RNA (siRNA)
duplexes has extended the RNA interference (RNAi) technique
to a wide range of common mammalian culture lines (17),
suggesting that this might represent an appropriate approach to
this problem. RNAi is the phenomenon by which double-
stranded RNA, acting through an incompletely characterized
nuclease complex, catalytically destroys mRNA transcripts con-
taining an identical nucleotide sequence, thereby suppressing
protein expression (18). Here we report the development of a
highly effective and specific RNAi method for depleting -ar-
restins from human cells. We rigorously validate this approach
in a variety of systems representing each of the currently known
classes of -arrestin action: desensitization, internalization, and
signaling.
Materials and Methods
Materials. Tissue culture reagents were purchased from Invitro-
gen. A horseradish peroxidase-conjugated secondary antibody
was from Amersham Pharmacia, and the Supersignal chemilu-
minescence reagent was from Pierce. The radiolabeled com-
pounds [125I]Tyr-4-angiotensin II (AngII) and [3H]cAMP were
obtained from NEN. Human AngII was from Peninsula Labo-
ratories. All other reagents were purchased from Sigma.
Synthesis of siRNAs. Chemically synthesized, double-stranded
siRNAs, with 19-nt duplex RNA and 2-nt 3 dTdT overhangs,
were purchased from Dharmacon Research (Lafayette, CO) or
Xeragon (Germantown, MD) in deprotected and desalted form.
To design -arrestin-specific siRNA duplexes, the mRNA se-
quences for human -arrestins 1 and 2 were screened for unique
21-nt sequences in the National Center for Biotechnology In-
formation database by using the BLAST search algorithm. The
accession numbers in brackets given below are from GenBank.
The siRNA sequences targeting -arrestin 1 (NM020251) and
-arrestin 2 (NM004313) are 5-AAAGCCUUCUGCGCG-
GAGAAU-3 and 5-AAGGACCGCAAAGUGUUUGUG-3
and correspond to the positions 439–459 and 201–221 relative to
the start codon, respectively. One small RNA duplex was syn-
thesized and used as a control. This RNA, initially designed to
target another -arrestin 2 mRNA unique sequence (5-
AAGUGGACCCUGUAGAUGGCG-3; position 101–120
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from the start codon), has no silencing effects on -arrestin
expression.
Cell Culture and Transfection. HEK293 cells were maintained as
described (19). Forty to 50% confluent cells in 100-mm plates,
split at least 24 h before transfection, were transfected with
siRNA using the GeneSilencer transfection reagent (Gene Ther-
apy Systems, San Diego) according to the modified manufac-
turer’s instructions. Briefly, 50 l of the GeneSilencer transfec-
tion reagent was added to 300 l of MEM, while RNA mixtures
containing 72 l of 20 M (20 g) RNA, 240 l of siRNA
diluent, and 180 l of MEM were prepared. Both solutions were
allowed to stand 5–10 min at room temperature and mixed by
inversion. After a 10–20-min incubation at room temperature,
the entire transfection mixture was added to cells in a 100-mm
plate containing 3–4 ml of fresh, serum-free MEM. After cells
were incubated for 4 h at 37°C, an additional 4–5 ml of MEM
with 20% FBS and 2% penicillinstreptomycin were added to the
plate. After additional incubation for 48 h, cells were divided into
12-well plates for -arrestin immunoblotting and further exper-
iments. For assays requiring transient receptor expression, the
appropriate amounts of the plasmid encoding the selected
receptor were transfected either 2 days after RNA treatment
(2-AR, 2-adrenergic receptor) or simultaneously with RNA
(AT1A-R, AngII type 1A receptor) as above. All assays were
performed at least 3 days after RNA transfection.
-Arrestin Immunoblotting. Whole-cell lysates, normalized for
equal amounts of protein, were separated by SDSPAGE on
10% Tris-Glycine polyacrylamide gels (Invitrogen) and immu-
noblotted with a 1:3,000 dilution of the rabbit polyclonal anti-
-arrestin antibody A1CT (15). -arrestins 1 and 2 immunoblots
were quantified by densitometry with a Fluor-S MultiImager
(Bio-Rad).
cAMP Accumulation Assays. Isoproterenol-stimulated cAMP accu-
mulation in cells was measured as described (20) and normalized
to total forskolin-stimulated cAMP production.
Receptor Sequestration Assays. Agonist-induced sequestration of
transiently expressed Flag epitope-tagged 2-ARs and AT1A-Rs
were defined as loss of cell surface receptors after agonist
treatment, measured by immunofluorescence flow cytometry
(21), and radioligand binding (22), respectively, as described.
ERK Activation Assays. ERK 12 MAPK activation in cells was
determined as increased levels of phosphorylated ERK 12 on
various concentrations of agonist treatment, measured essen-
tially as described (10). Dose–response curves and EC50s were
analyzed with PRISM software (GraphPad, San Diego).
Results
Two small RNA duplexes corresponding to the -arrestin 1 and
2 genes were chemically synthesized and transfected into
HEK293 cells to test their ability to silence -arrestin expression.
Protein expression levels of -arrestins 1 and 2 in siRNA-
transfected cells were analyzed by immunoblotting the whole-cell
lysates (Fig. 1). Transfection of -arrestins 1 or 2 siRNA reduces
expression of the targeted -arrestin by 70% and 90%, respec-
tively, compared with either nonsilencing, control RNA- or
mock-transfected cells. Both siRNAs also show significant iso-
form specificity. Moreover, dual transfection with both siRNAs
significantly reduces the amount of -arrestins 1 and 2. These
results validate our siRNAs as potent reagents capable of
selectively or collectively depleting -arrestin levels in human
cells.
-arrestins 1 and 2 have been ascribed roles in both 7MS
receptor desensitization and internalization (2–6). We first
tested the ability of cells transfected with siRNAs targeting the
-arrestins to support agonist-induced desensitization of the
endogenously expressed 2-AR by measuring the accumulation
of the second messenger cAMP. Stimulation of the 2-AR with
isoproterenol for 2 min leads to maximal levels of cAMP
accumulated in our HEK293 cells (data not shown). After
agonist treatment for 2 min, total cAMP accumulation is sig-
nificantly elevated in cells with -arrestin 2 siRNA, whereas cells
transfected with -arrestin 1 siRNA show no change relative to
controls (Fig. 2). These results demonstrate that reducing
-arrestin 2 levels (85–95%; Fig. 1) by RNAi provides a func-
tional KO with respect to desensitization of the 2-AR. Addi-
tionally, these data are also in agreement with studies showing
that the 2-AR preferentially recruits -arrestin 2 following
agonist stimulation (19).
Next, we examined the effect of siRNA-suppressed -arrestin
expression on internalization of 7MS receptors by using tran-
siently expressed 2-ARs and AT1A-Rs. Flag epitope-tagged
2-AR internalization was measured by flow cytometry after
isoproterenol treatment for 30 min. Analogous to 2-AR desen-
sitization, agonist-induced receptor internalization is dramati-
cally attenuated in -arrestin 2 siRNA-transfected cells, whereas
-arrestin 1 siRNA shows no significant effect on 2-AR inter-
nalization (Fig. 3A). These data are also consistent with our
previous results in MEF lines originated from -arrestin KO
mice, suggesting that -arrestin 2 is critical for regulating 2-AR
sequestration, whereas -arrestin 1 is largely dispensable for this
function (16).
Sequestration of the AT1A-R, a representative of a 7MS
receptor group interacting with both -arrestins 1 and 2 with
approximately equal affinity (19), was measured 5 min after
Fig. 1. Analysis of -arrestin expression in siRNA-transfected HEK293 cells.
Whole-cell lysates were prepared from the indicated RNA-transfected HEK293
cells as described. Equal amounts of proteins (20g) in each sample were used
to determine expression of -arrestins 1 and 2 by immunoblotting with the
polyclonal anti--arrestin antibody A1CT. Values shown are expressed as
percent of the level of each -arrestin in mock (No RNA)-transfected cells and
represents the mean  SE from seven independent experiments. Statistical
significance was determined by using a one-way ANOVA to correct for mul-
tiple comparisons (PRISM software) between -arrestin siRNA-transfected cells
and control cells [both mock and nonsilencing, control RNA (CTL)-transfected]
(*, P  0.001). A representative immunoblot is shown (Upper).
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AngII treatment by using ligand-binding assays. The AT1A-R
shows a very different pattern in siRNA effects on its agonist-
induced internalization (Fig. 3B) from that of the 2-AR (Fig.
3A). -arrestin 1 siRNA-transfected cells show a modest, but
significant, reduction (35%) in AT1A-R sequestration, whereas
transfection of -arrestin 2 siRNA, more effective in suppressing
the -arrestin level (Fig. 1), results in 60% attenuation of
receptor internalization. The combination of both siRNAs,
however, fails to further inhibit AT1A-R sequestration. Although
the dual transfection decreases levels of both -arrestins 1 and
2, it is not as effective as single transfection, particularly for
-arrestin 2 (Fig. 1). Thus, residual amounts of -arrestin 2 in
the double-transfected cells may prevent further inhibition
of AT1A-R internalization, or alternatively, there may be a
-arrestin-independent pathway for AT1A-R internalization.
Furthermore, at longer stimulation times (15 min), the level of
receptor sequestration in the -arrestin-suppressed cells be-
comes equal to the controls (data not shown), confirming that at
these levels (Fig. 1) of residual -arrestins, the major effect is to
slow the rate of internalization of the AT1A-R.
Besides its classical roles in desensitization and internalization
of 7MS receptors, -arrestin has recently been demonstrated to
facilitate propagation of signals from the receptor to a variety of
MAPK signaling systems such as the MAPKs ERK 12 (7–10),
JNK 3 (11), and p38 (12) by scaffolding those kinases. To test
whether siRNA-mediated depletion of -arrestin alters MAPK
signaling from the activated 7MS receptor, we examined ERK
12 activation by transiently expressed AT1A-R. As shown in Fig.
4, the maximal activation of ERK 12 in response to high
concentrations of AngII (106 M) is not different between
-arrestin 2 siRNA- and nonsilencing, control RNA-transfected
cells. The dose–response curve, however, is shifted to higher
concentrations of ligands by siRNA-mediated -arrestin 2 de-
pletion compared with that of control cells. The EC50 of ERK
12 activation in response to AngII is 7-fold higher in -arrestin
2 siRNA-transfected cells than in control siRNA-transfected
cells. These results directly demonstrate that -arrestin acts as a
positive regulator in 7MS receptor-mediated MAPK signaling.
Discussion
Since their discovery more than a decade ago as molecules that
desensitize 7MS receptors (14, 15), the roles of -arrestins in
these receptor systems have strikingly expanded (23, 24). Over-
expression of wild-type or dominant-negative mutant -arrestins
have been commonly used strategies to characterize currently
known -arrestin functions. However, because endogenously
expressed levels of -arrestins may not be limiting, overexpres-
sion of the wild-type may fail to potentiate -arrestin-dependent
cellular responses. Moreover, since -arrestins are noncatalytic
proteins that bind various signaling molecules through distinct
epitopes (24), dominant-negative mutants, developed for one
purpose (e.g., to block sequestration), may fail or give misleading
results when used to assess another.
Depletion of -arrestin by various methods has also been used
as an alternative approach to overcome such obstacles in study-
Fig. 2. Effect of siRNA-mediated-arrestin depletion on cAMP accumulation
by endogenously expressed 2-AR. HEK293 cells were transfected with the
indicated RNA oligonucleotides as described and subsequently stimulated
with 10 M isoproterenol for 2 min. Accumulation of cAMP was determined
by competition with [3H]cAMP for PKA binding sites and then normalized to
total forskolin (10 M)-stimulated cAMP levels for each treatment. Data are
expressed as percent of agonist-induced cAMP accumulation in control RNA-
treated (CTL) cells and represent the mean  SE of six independent experi-
ments. NS, nonstimulated. Statistical significance was determined by using a
one-way ANOVA to correct for multiple comparisons between -arrestin
siRNA-transfected cells and control cells. The asterisk indicates P  0.05 vs.
both control RNA- and mock (No RNA)-transfected cells.
Fig. 3. Effect of siRNA-mediated suppression of -arrestin levels on 7MS
receptor internalization. (A) HEK293 cells were transfected with either control
RNA (CTL) or the indicated -arrestin siRNA and subsequently transfected again
with plasmids encoding Flag epitope-tagged 2-AR as described. Serum-starved
cells were exposed to 10 M isoproterenol for 30 min at 37°C and analyzed for
their plasma membrane content of the Flag epitope-tagged 2-AR by flow
cytometry. Values shown are expressed as percentage of loss of agonist-induced
cell surface receptors over nonstimulated cells. (B) HEK293 cells were transfected
with appropriate amounts of AT1A-R encoding plasmids and the indicated siRNAs
simultaneously. Receptor expression was equivalent (200–300 fmol per mg of
protein) among all transfected cells. Cells were cooled down in ice-cold, serum-
free media and subsequently stimulated with 0.2 nM 125I-labeled AngII for 5 min
at 37°C. Percent of agonist-stimulated AT1A-R sequestration was determined as
acid-resistant cpm divided by the total cpm bound. Data represent the meanSE
from three independent experiments done in triplicate. Statistical significance
was determined by using a one-way ANOVA to correct for multiple comparisons
between -arrestin siRNA-transfected cells and control cells [both receptor-
transfected cells without RNA (Rc alone) and control RNA-treated cells]
(*, P 0.05; **, P 0.01).
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ing its roles in 7MS receptor systems. One such method is
antisense oligonucleotides. This technique, however, only mod-
estly attenuates -arrestin expression and is associated with low
isoform-selectivity (25). Recently developed -arrestin KO mice
and MEF lines derived from them have been valuable tools to
expand our understanding of physiological and cellular functions
of -arrestin (16). However, MEF lines are not applicable to the
study of potentially variable roles of these multifunctional pro-
teins in diverse cell types. Thus, we have chosen to use RNAi,
with its potential for high silencing efficiency and selectivity in
multiple cell types (17), as a new method to investigate the
consequences of reduced -arrestin levels in cultured cells.
Here, we show that transfection of siRNA designed to target
-arrestins 1 or 2 markedly and reliably attenuates expression of
each -arrestin, interfering with their currently known functions
in 7MS receptor systems. Although some cross-reactivity to the
opposite -arrestin is observed (Fig. 1), our siRNAs show highly
isoform-selective effects on 2-AR desensitization (Fig. 2) and
sequestration (Fig. 3A); introduction of -arrestin 2 siRNA
attenuates both desensitization and sequestration of the 2-AR,
whereas -arrestin 1 siRNA has no effect. Thus, the siRNAs used
here provide functionally selective depletion of a designated
isoform of -arrestin and are thereby useful to elucidate non-
redundant, isoform-specific functions of -arrestins.
While the advantages of using RNAi to examine roles of specific
proteins are numerous and represent a significant improvement
over alternative methods (18), there are caveats that need to be
addressed when using this technique. Foremost among these is the
impossibility of complete silencing of the target protein in siRNA-
transfected cells. Studies using confocal microscopy strongly suggest
that this phenomenon is limited by the transfection efficiency of the
experimental cell population (17, 18). The method used in the
present study makes it possible to achieve over 90% transfection
efficiency in our HEK293 cells (data not shown). Furthermore, the
extent of reduction of -arrestin levels that we observed was
sufficient in all cases to cause functional impairment of -arrestin-
mediated mechanisms. Secondly, using multiple siRNAs simulta-
neously may yield different results than either reagent individually
(18). Such is the case for the dual transfection of -arrestins 1 and
2 siRNAs. Although both -arrestins are significantly depleted, the
combination is not quite as effective at silencing -arrestin 2 as the
-arrestin 2 siRNA alone. Undoubtedly, future advances in under-
standing the mechanisms underlying RNAi will result in improve-
ments in this area.
To date, the best system for examining the functional conse-
quences of loss of -arrestins has been MEF lines established from
-arrestin KO mice (16). Our siRNA treatment produces patterns
in desensitization (Fig. 2) and internalization (Fig. 3) of 7MS
receptors similar to those in these MEF cells. We observed signif-
icant impairment in desensitization and sequestration of the 2-AR
by depletion of -arrestin 2, but not -arrestin 1, as well as in
internalization of the AT1A-R by suppression of both -arrestins 1
and 2 expression. The data here is also in accord with the previous
finding that -arrestin 2 is recruited to the 2-AR with a 10-fold-
higher affinity than -arrestin 1, whereas the AT1A-R recruits both
-arrestins with approximately equal efficacy (19).
Depletion of a single -arrestin isoform by RNAi significantly
reduces AT1A-R internalization after short time exposure (5
min) to AngII but shows no effect with longer stimulation time
(15 min; data not shown). These results suggest that the
siRNA-mediated reduction of the -arrestin level functions to
slow the rate of internalization of the AT1A-R rather than to
block this process. Furthermore, it has been demonstrated that
the AT1A-R is also internalized through -arrestin-independent
pathways (26). MEF cells from mice devoid of -arrestins also
fail to completely abolish the sequestration of the AT1A-R (16).
We found that siRNA-mediated depletion of -arrestin2 shifts
the dose–response curve for ERK activation in response to AT1A-R
stimulation to the right but has no effect on the maximal response
to a high concentration of agonist. Because MAPKs can be
activated through multiple signaling pathways upon 7MS receptor
activation (27, 28), it likely is not possible to abolish their activation
by knocking out only a single pathway such as a -arrestin-
dependent pathway. Nonetheless, our results directly demonstrate
that -arrestin acts as a signal transducer for 7MS receptor-
mediated MAPK activation, a conclusion that is also supported by
previous findings that overexpression of-arrestin potentiates ERK
activation by various 7MS receptors (9, 10). In the future, it will be
of interest to determine whether suppression of both -arrestin
isoforms has even more profound effects on ERK activation.
Our results demonstrate that siRNA-mediated suppression of
the -arrestin levels is sufficient to alter the currently known
-arrestin functions in 7MS receptor systems: desensitization,
internalization, and signaling. A growing list of newly discovered
roles of -arrestins as adapter proteins and scaffolds for prop-
agating signals in a variety of 7MS receptor systems (24) suggests
that our appreciation of the functions of these proteins will most
likely continue to expand. Thus, the results reported here
introduce the RNAi technique as a reliable and powerful
approach to expose unrevealed, physiological, and cellular func-
tions of these versatile proteins in the future.
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assistance. This work was supported by National Institutes of Health
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Fig. 4. Effect of siRNA-inhibited expression of -arrestin on ERK activation in
response to AT1A-R stimulation. HEK293 cells transiently expressing AT1A-R (300
fmol per mg of protein) by cotransfection with either control RNA (CTL) or the
-arrestin2siRNAwereserum-starvedfor1–2handstimulatedwiththeindicated
concentrations of AngII for 5 min at 37°C. Phosphorylation of ERK in whole-cell
lysates, normalized to equal amounts of proteins in each sample, was detected by
immunoblotting with an antiphospho-ERK 12 antibody as described. Equal
loading of total ERK proteins were also confirmed by immunoblotting with an
anti-ERK 12 antibody (data not shown). Each data point is expressed as percent
of the maximal phosphorylation of ERK in response to 106 M AngII in control
cells and represents the mean SE from seven independent experiments. Dose–
response curves and EC50s between control RNA- and -arrestin 2 siRNA-treated
samples were obtained and analyzed by a two-way ANOVA to determine statis-
tical significance for shift of the curve (P  0.001) by using PRISM software. A
representative immunoblot is shown (Upper).
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